Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04237831 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT04237831 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 30 participants.
The verdict
NCT04237831, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
A study to evaluate the drug effect, safety, and tolerability of BMS-986259 in participants with different levels of kidney function
Interventions
- DRUG BMS-986259
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-02-26 |
| Est. Completion | 2021-07-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04237831
The ClinicalTrials.gov registry entry for NCT04237831 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-986259 is the first listed.
NCT04237831 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04237831 about?
NCT04237831 is a clinical study titled "A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function". A study to evaluate the drug effect, safety, and tolerability of BMS-986259 in participants with different levels of kidney function
What is the current status of trial NCT04237831?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2020-02-26. Estimated completion is 2021-07-16.
What interventions are being tested in trial NCT04237831?
The interventions under investigation include: BMS-986259 (DRUG).
Who is sponsoring clinical trial NCT04237831?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.